Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 5/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | GIPR | P48546 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209364 | 0.90 | HSD11B1 (0.46) | HSD11B1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL208293 | 0.87 | HSD11B1 (0.43) | HSD11B1ALDH1A1ATMSMN1; SMN2NPSR1 | |
| SCHEMBL208203 | 0.86 | EPHX2 (0.40) | HSD11B1PDE4BPDE4DEPHX2CHKA | |
| SCHEMBL13266278 | 0.85 | HSD11B1 (0.44) | HSD11B1ALDH1A1ATMSMN1; SMN2NPSR1 | |
| SCHEMBL208290 | 0.85 | HSD11B1 (0.38) | HSD11B1PDE4BPDE4DSLC6A4HRH3 | |
| SCHEMBL209250 | 0.84 | EPHX2 (0.40) | HSD11B1EPHX2SLC6A4HRH3 | |
| SCHEMBL14391256 | 0.84 | HSD11B1 (0.39) | HSD11B1SLC6A4HRH3 | |
| SCHEMBL209411 | 0.84 | HSD11B1 (0.39) | HSD11B1SLC6A4HRH3 | |
| SCHEMBL207750 | 0.84 | EPHX2 (0.43) | HSD11B1EPHX2SLC6A4HRH3 | |
| SCHEMBL209360 | 0.84 | HSD11B1 (0.38) | HSD11B1ALDH1A1PDE4BPDE4DGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016047-B1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8088776-B2 | Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090156571-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | disclosed |
| EP-2016047-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007124337-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156571-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885ALDH1A1 88/4885ATM 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.